MA51902A - Schémas posologiques d'anticorps b7-h4 - Google Patents

Schémas posologiques d'anticorps b7-h4

Info

Publication number
MA51902A
MA51902A MA051902A MA51902A MA51902A MA 51902 A MA51902 A MA 51902A MA 051902 A MA051902 A MA 051902A MA 51902 A MA51902 A MA 51902A MA 51902 A MA51902 A MA 51902A
Authority
MA
Morocco
Prior art keywords
dosage schedules
antibodies dosage
antibodies
schedules
dosage
Prior art date
Application number
MA051902A
Other languages
English (en)
Inventor
Helen L Collins
Sandeep P Inamdar
Hong Xiang
Xiang Zhang
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MA51902A publication Critical patent/MA51902A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA051902A 2018-02-21 2019-02-21 Schémas posologiques d'anticorps b7-h4 MA51902A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US201962802100P 2019-02-06 2019-02-06

Publications (1)

Publication Number Publication Date
MA51902A true MA51902A (fr) 2021-05-26

Family

ID=65686103

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051902A MA51902A (fr) 2018-02-21 2019-02-21 Schémas posologiques d'anticorps b7-h4

Country Status (13)

Country Link
US (3) US20210070862A1 (fr)
EP (1) EP3755719A1 (fr)
JP (2) JP7258038B6 (fr)
KR (1) KR102863169B1 (fr)
CN (1) CN111868089B (fr)
AU (1) AU2019226009B2 (fr)
BR (1) BR112020016990A2 (fr)
CA (1) CA3091161A1 (fr)
IL (1) IL276623A (fr)
MA (1) MA51902A (fr)
MX (1) MX2020008730A (fr)
SG (1) SG11202007820QA (fr)
WO (1) WO2019165075A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070774A1 (fr) * 2017-08-25 2019-02-28 Five Prime Therapeutics, Inc. Anticorps anti-b7-h4 et leurs procedes d'utilisation
EP3755720A1 (fr) * 2018-02-21 2020-12-30 Five Prime Therapeutics, Inc. Formulations d'anticorps b7-h4
AU2019228600A1 (en) 2018-03-02 2020-09-24 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
CN113166242B (zh) * 2018-10-15 2024-11-19 戊瑞治疗有限公司 用于癌症的组合疗法
CA3203721A1 (fr) 2021-01-04 2022-07-07 Timothy B. Lowinger Conjugues anticorps-medicament ciblant b7-h4 et leurs methodes d'utilisation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
EP1333032A4 (fr) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk Procede de purification d'un anticorps
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
CA2838062C (fr) 2001-08-03 2015-12-22 Roche Glycart Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US7601891B2 (en) 2002-03-19 2009-10-13 Plant Research International B.V. Optimizing glycan processing plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
PL222220B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Komórka gospodarza i sposób wytwarzania polipeptydu w komórce gospodarza
CA2605781A1 (fr) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
NZ598048A (en) 2006-01-17 2013-05-31 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of n-glycans in plants
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
CA2845536A1 (fr) * 2011-08-15 2013-02-21 Amplimmune, Inc. Anticorps anti-b7-h4 et leurs utilisations
SG11201504764SA (en) * 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
ME03476B (fr) 2013-08-01 2020-01-20 Five Prime Therapeutics Inc Anticorps anti-fgfr2iiib non fucosilés
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
CA3070774A1 (fr) * 2017-08-25 2019-02-28 Five Prime Therapeutics, Inc. Anticorps anti-b7-h4 et leurs procedes d'utilisation
EP3755720A1 (fr) * 2018-02-21 2020-12-30 Five Prime Therapeutics, Inc. Formulations d'anticorps b7-h4

Also Published As

Publication number Publication date
BR112020016990A2 (pt) 2021-02-23
EP3755719A1 (fr) 2020-12-30
JP7258038B2 (ja) 2023-04-14
JP2023089063A (ja) 2023-06-27
JP7258038B6 (ja) 2023-04-25
US20240317864A1 (en) 2024-09-26
CN111868089A (zh) 2020-10-30
CN111868089B (zh) 2025-08-22
US20230287123A1 (en) 2023-09-14
JP2021513997A (ja) 2021-06-03
KR20200123169A (ko) 2020-10-28
AU2019226009A1 (en) 2020-09-03
IL276623A (en) 2020-09-30
SG11202007820QA (en) 2020-09-29
AU2019226009B2 (en) 2025-11-20
WO2019165075A1 (fr) 2019-08-29
CA3091161A1 (fr) 2019-08-29
MX2020008730A (es) 2020-12-07
US20210070862A1 (en) 2021-03-11
KR102863169B1 (ko) 2025-09-22

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
EP3883970A4 (fr) Anticorps anti-b7-h3
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA49043A (fr) Formulation stable d'anticorps
MA51903A (fr) Formulations d'anticorps b7-h4
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
EP3299383A4 (fr) MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
MA55600A (fr) Anticorps anti-ige
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
EP3601604A4 (fr) Détection multiple d'anticorps spécifiques à un isotype
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
EP3938401A4 (fr) Récepteurs d'antigènes chimériques anti-bcma
EP3841125A4 (fr) Anticorps monoclonaux contre tim-3 humain
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3831851A4 (fr) Anticorps anti-btla
MA52152A (fr) Anticorps
MA54052A (fr) Formulation d'anticorps
MA56466A (fr) Anticorps anti-epha4
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
MA54139A (fr) Formulation d'anticorps
MA54464A (fr) Anticorps humanisé anti-récepteur de l'igf-i